Elementis
ELM · Main Market · Chemicals · mcap £1,046m · 181.2p 2 open situations →
Open · 2
Elevate Elementis cost savings programme
Elevate Elementis launched in July 2025 with a net $10m savings target, additional to $30m of savings from 2024-25. In H1 2026 net savings were $0.5m ($1.3m savings less $0.8m extra R&D), taking delivery to $6.5m; management is on track for $4m net in 2026.
- H1 net savings
- $0.5m ($1.3m savings less $0.8m incremental R&D investment) 30 Jul 2026 ↗
- Delivered to date
- $6.5m of the net $10m target since launch 30 Jul 2026 ↗
- 2026 target
- Total net savings of $4m by end of 2026 30 Jul 2026 ↗
Next: deliver total net savings of $4m by end of 2026 · 31 Dec 2026
- 30 Jul 2026 $6.5m of net $10m target delivered
- 5 Mar 2026 $18m delivered in 2025; $4m remaining
- 5 Mar 2026 $18m delivered in 2025; $4m remaining
- 21 Jan 2026 Margin gains and bolt-on cited as delivery
Pharma proceeds share buyback
The sale of the pharma business to ABF was agreed on 5 March 2026 with net cash proceeds to be returned to shareholders, and completed on 2 June 2026. The H1 results of 30 July 2026 confirm a new c£25m (c$35m) buyback has been launched, with net debt at $163.8m (1.1x EBITDA).
- Size
- c£25m (c$35m) 30 Jul 2026 ↗
- Funding
- Net cash proceeds from sale of the pharmaceutical manufacturing business 30 Jul 2026 ↗
- Status
- Launched, announced with H1 results on 30 July 2026 30 Jul 2026 ↗
- Net debt
- $163.8m at 30 June 2026, 1.1x EBITDA 30 Jul 2026 ↗
Next: buyback execution using pharma sale proceeds
- 30 Jul 2026 New c£25m buyback launched
Closed · 2
Company filings. Not investment advice.